BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 33642890)

  • 21. Dynamics of Plasma EGFR T790M Mutation in Advanced NSCLC: A Multicenter Study.
    Yang Z; Li J; Hu Y; Chen M; Peng D; Zong D; Shang Q; Tao L; Zhao Y; Ni Y; Ye J; Xie Y; Yang L; Lin Q; Cai C; Xu N; Huang X; Dong X; Zhou Z; Yu Y; Shangguan Z; Xu Y; Ying W; Weng M; Yuan Z; Dong Z; Li J; Zheng Z; Pan J; Liu L; Ye J; Zhang Z; Li W; Zhu J; Jin S; Li Y; Ding C
    Target Oncol; 2019 Dec; 14(6):719-728. PubMed ID: 31691892
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Performance of different methods for detecting T790M mutation in the plasma of patients with advanced NSCLC after developing resistance to first-generation EGFR-TKIs in a real-world clinical setting.
    Hou T; Zeng J; Xu H; Su S; Ye J; Li Y
    Mol Clin Oncol; 2022 Apr; 16(4):88. PubMed ID: 35251639
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Longitudinal monitoring of EGFR mutations in plasma predicts outcomes of NSCLC patients treated with EGFR TKIs: Korean Lung Cancer Consortium (KLCC-12-02).
    Lee JY; Qing X; Xiumin W; Yali B; Chi S; Bak SH; Lee HY; Sun JM; Lee SH; Ahn JS; Cho EK; Kim DW; Kim HR; Min YJ; Jung SH; Park K; Mao M; Ahn MJ
    Oncotarget; 2016 Feb; 7(6):6984-93. PubMed ID: 26755650
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Highly Sensitive Droplet Digital PCR Method for Detection of de novo EGFR T790M Mutation in Patients with Non-Small Cell Lung Cancer.
    Wang X; Li X; Guo H; Zhu L; Peng Z; Wang J; Yang F; Guo Y
    Onco Targets Ther; 2020; 13():10621-10630. PubMed ID: 33116639
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Predictive impact of low-frequency pretreatment T790M mutation in patients with EGFR-mutated non-small cell lung cancer treated with EGFR tyrosine kinase inhibitors.
    Matsumoto Y; Sawa K; Fukui M; Oyanagi J; Yoshimoto N; Suzumura T; Watanabe T; Kaneda H; Mitsuoka S; Asai K; Kimura T; Yamamoto N; Hirata K; Koh Y; Kawaguchi T
    Lung Cancer; 2020 Jan; 139():80-88. PubMed ID: 31751804
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Developing Ultrasensitive Library-Aliquot-Based Droplet Digital PCR for Detecting T790M in Plasma-Circulating Tumor DNA of Non-small-Cell-Lung-Cancer Patients.
    Yang K; Li J; Zhao J; Ren P; Wang Z; Wei B; Dong B; Sun R; Wang X; Groen HJM; Ma J; Guo Y
    Anal Chem; 2018 Oct; 90(19):11203-11209. PubMed ID: 30156405
    [TBL] [Abstract][Full Text] [Related]  

  • 27.
    Buder A; Hochmair MJ; Setinek U; Pirker R; Filipits M
    Transl Lung Cancer Res; 2020 Apr; 9(2):239-245. PubMed ID: 32420063
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Acquisition of the T790M resistance mutation during afatinib treatment in EGFR tyrosine kinase inhibitor-naïve patients with non-small cell lung cancer harboring
    Tanaka K; Nosaki K; Otsubo K; Azuma K; Sakata S; Ouchi H; Morinaga R; Wataya H; Fujii A; Nakagaki N; Tsuruta N; Takeshita M; Iwama E; Harada T; Nakanishi Y; Okamoto I
    Oncotarget; 2017 Sep; 8(40):68123-68130. PubMed ID: 28978102
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Next-generation sequencing of tissue and circulating tumor DNA: Resistance mechanisms to EGFR targeted therapy in a cohort of patients with advanced non-small cell lung cancer.
    Zhang Y; Xiong L; Xie F; Zheng X; Li Y; Zhu L; Sun J
    Cancer Med; 2021 Jul; 10(14):4697-4709. PubMed ID: 34173341
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Detection of EGFR-Activating and T790M Mutations Using Liquid Biopsy in Patients With EGFR-Mutated Non-Small-Cell Lung Cancer Whose Disease Has Progressed During Treatment With First- and Second-Generation Tyrosine Kinase Inhibitors: A Multicenter Real-Life Retrospective Study.
    Minari R; Mazzaschi G; Bordi P; Gnetti L; Alberti G; Altimari A; Gruppioni E; Sperandi F; Parisi C; Guaitoli G; Bettelli S; Longo L; Bertolini F; Pagano M; Bonelli C; Tagliavini E; Nicoli D; Ubiali A; Zangrandi A; Trubini S; Proietto M; Fiorentino M; Tiseo M;
    Clin Lung Cancer; 2020 Sep; 21(5):e464-e473. PubMed ID: 32276870
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Clinical value of droplet digital polymerase chain reaction method in detecting plasma circulating tumor deoxyribonucleic acid epidermal growth factor receptor mutations in advanced pulmonary adenocarcinoma patients].
    Ma L; Lü JL; Li K; Wang JH; Yang XJ; Li X; Zhang H; Zhang Q; Qin N; Zhang SC
    Zhonghua Yi Xue Za Zhi; 2018 Aug; 98(29):2336-2340. PubMed ID: 30107692
    [No Abstract]   [Full Text] [Related]  

  • 32. Plasma EGFR T790M ctDNA status is associated with clinical outcome in advanced NSCLC patients with acquired EGFR-TKI resistance.
    Zheng D; Ye X; Zhang MZ; Sun Y; Wang JY; Ni J; Zhang HP; Zhang L; Luo J; Zhang J; Tang L; Su B; Chen G; Zhu G; Gu Y; Xu JF
    Sci Rep; 2016 Feb; 6():20913. PubMed ID: 26867973
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Detection of EGFR mutation of pulmonary adenocarcinoma in sputum using droplet digital PCR.
    Isaka T; Yokose T; Ito H; Nakayama H; Miyagi Y; Saito H; Masuda M
    BMC Pulm Med; 2021 Mar; 21(1):100. PubMed ID: 33757469
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Monitoring EGFR T790M with plasma DNA from lung cancer patients in a prospective observational study.
    Sueoka-Aragane N; Katakami N; Satouchi M; Yokota S; Aoe K; Iwanaga K; Otsuka K; Morita S; Kimura S; Negoro S;
    Cancer Sci; 2016 Feb; 107(2):162-7. PubMed ID: 26577492
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Dynamics of EGFR mutations in plasma recapitulates the clinical response to EGFR-TKIs in NSCLC patients.
    Xiong L; Cui S; Ding J; Sun Y; Zhang L; Zhao Y; Gu A; Chu T; Wang H; Zhong H; Ye X; Gu Y; Zhang X; Hu M; Jiang L
    Oncotarget; 2017 Sep; 8(38):63846-63856. PubMed ID: 28969034
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Digital PCR analysis of plasma cell-free DNA for non-invasive detection of drug resistance mechanisms in EGFR mutant NSCLC: Correlation with paired tumor samples.
    Ishii H; Azuma K; Sakai K; Kawahara A; Yamada K; Tokito T; Okamoto I; Nishio K; Hoshino T
    Oncotarget; 2015 Oct; 6(31):30850-8. PubMed ID: 26334838
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Clinical significance of repeat rebiopsy in detecting the EGFR T790M secondary mutation in patients with non-small cell lung cancer.
    Ichihara E; Hotta K; Kubo T; Higashionna T; Ninomiya K; Ohashi K; Tabata M; Maeda Y; Kiura K
    Oncotarget; 2018 Jun; 9(50):29525-29531. PubMed ID: 30034635
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Detection of
    Nizamaddin SK; Mehrotra M; Nadhim ASH; Luthra R; Roy-Chowdhuri S
    Arch Pathol Lab Med; 2020 Jan; ():. PubMed ID: 31904278
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Detection of epidermal growth factor receptor mutations in exhaled breath condensate using droplet digital polymerase chain reaction.
    Nishii K; Ohashi K; Tamura T; Ninomiya K; Matsubara T; Senoo S; Kano H; Watanabe H; Oda N; Makimoto G; Higo H; Kato Y; Ninomiya T; Kubo T; Yamamoto H; Tomida S; Hotta K; Tabata M; Toyooka S; Maeda Y; Kiura K
    Oncol Lett; 2020 Dec; 20(6):393. PubMed ID: 33193853
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Digital PCR-Based Detection of EGFR Mutations in Paired Plasma and CSF Samples of Lung Adenocarcinoma Patients with Central Nervous System Metastases.
    Huang R; Xu X; Li D; Chen K; Zhan Q; Ge M; Zhou X; Liang X; Guan M
    Target Oncol; 2019 Jun; 14(3):343-350. PubMed ID: 31161597
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.